A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: Modelling study
| Autor: | Samiul A. Mostafa, Clare L Gillies, Nick Taub, Stephen L. Hiles, Keith R. Abrams, Kamlesh Khunti, Melanie J. Davies |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Population Primary care Type 2 diabetes Models Biological Sensitivity and Specificity Diagnostic Techniques Endocrine Endocrinology Internal medicine Diabetes mellitus Glucose Intolerance Internal Medicine Humans Mass Screening Medicine Blood test education Aged education.field_of_study Framingham Risk Score medicine.diagnostic_test business.industry Decision Trees Type 2 Diabetes Mellitus General Medicine Middle Aged medicine.disease United Kingdom Surgery Models Economic Diabetes Mellitus Type 2 Female Blood sugar regulation business |
| Zdroj: | Diabetes Research and Clinical Practice. 97:505-513 |
| ISSN: | 0168-8227 |
| DOI: | 10.1016/j.diabres.2012.03.009 |
| Popis: | Background To determine a cost per case detected for different screening strategies for both Type 2 diabetes alone and in combination with impaired glucose regulation. Methods Bayesian framework modelling study using data from the ADDITION-Leicester screening study in UK multi-ethnic primary care setting. There were 5794 people aged 40–75 years (77.4% white European; 22.6% south Asian) without previously known diabetes. We compared 212 screening strategies including blood tests, a computer practice data score and a risk score, as part of a multi-stage process that all used an oral glucose tolerance test as the diagnostic test. Simulation models were created using sensitivity estimates for the expected cost per case. Results The estimated costs per case identified for the 18 most sensitive strategies varied from £457 to £1639 (€526–1886, for £1 = €1.15) for diabetes and £148–913 (€170–1050) for both diabetes and impaired glucose regulation. The lowest costing diabetes strategies ranged from £457 to £523 (€526–601) involving a two-stage screening strategy, a non-invasive risk stratifying tool followed by a blood test, producing sensitivities ranging from 67.1 to 82.4%. Conclusion Screening a population using a non-invasive risk stratification tool followed by a screening blood test is the most cost-effective method of screening for diabetes and abnormal glucose tolerance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect